Cargando…

Neuroimaging in Glucocerebrosidase‐Associated Parkinsonism: A Systematic Review

BACKGROUND: Mutations in the GBA gene cause Gaucher's disease (GD) and constitute the most frequent genetic risk factor for idiopathic Parkinson's disease (iPD). Nonmanifesting carriers of GBA mutations/variants (GBA‐NMC) constitute a potential PD preclinical population, whereas PD patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Filippi, Massimo, Balestrino, Roberta, Basaia, Silvia, Agosta, Federica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546404/
https://www.ncbi.nlm.nih.gov/pubmed/35521899
http://dx.doi.org/10.1002/mds.29047
_version_ 1784805035134156800
author Filippi, Massimo
Balestrino, Roberta
Basaia, Silvia
Agosta, Federica
author_facet Filippi, Massimo
Balestrino, Roberta
Basaia, Silvia
Agosta, Federica
author_sort Filippi, Massimo
collection PubMed
description BACKGROUND: Mutations in the GBA gene cause Gaucher's disease (GD) and constitute the most frequent genetic risk factor for idiopathic Parkinson's disease (iPD). Nonmanifesting carriers of GBA mutations/variants (GBA‐NMC) constitute a potential PD preclinical population, whereas PD patients carrying some GBA mutations/variants (GBA‐PD) have a higher risk of a more aggressive disease course. Different neuroimaging techniques are emerging as potential biomarkers in PD and have been used to study GBA‐associated parkinsonism. OBJECTIVE: The aim is to critically review studies applying neuroimaging to GBA‐associated parkinsonism. METHODS: Literature search was performed using PubMed and EMBASE databases (last search February 7, 2022). Studies reporting neuroimaging findings in GBA‐PD, GD with and without parkinsonism, and GBA‐NMC were included. RESULTS: Thirty‐five studies were included. In longitudinal studies, GBA‐PD patients show a more aggressive disease than iPD at both structural magnetic resonance imaging and 123‐fluoropropylcarbomethoxyiodophenylnortropane single‐photon emission computed tomography. Fluorodeoxyglucose‐positron emission tomography and brain perfusion studies reported a greater cortical involvement in GBA‐PD compared to iPD. Overall, contrasting evidence is available regarding GBA‐NMC for imaging and clinical findings, although subtle differences have been reported compared with healthy controls with no mutations. CONCLUSIONS: Although results must be interpreted with caution due to limitations of the studies, in line with previous clinical observations, GBA‐PD showed a more aggressive disease progression in neuroimaging longitudinal studies compared to iPD. Cognitive impairment, a “clinical signature” of GBA‐PD, seems to find its neuroimaging correlate in the greater cortical burden displayed by these patients as compared to iPD. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society
format Online
Article
Text
id pubmed-9546404
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-95464042022-10-14 Neuroimaging in Glucocerebrosidase‐Associated Parkinsonism: A Systematic Review Filippi, Massimo Balestrino, Roberta Basaia, Silvia Agosta, Federica Mov Disord Regular Issue Articles BACKGROUND: Mutations in the GBA gene cause Gaucher's disease (GD) and constitute the most frequent genetic risk factor for idiopathic Parkinson's disease (iPD). Nonmanifesting carriers of GBA mutations/variants (GBA‐NMC) constitute a potential PD preclinical population, whereas PD patients carrying some GBA mutations/variants (GBA‐PD) have a higher risk of a more aggressive disease course. Different neuroimaging techniques are emerging as potential biomarkers in PD and have been used to study GBA‐associated parkinsonism. OBJECTIVE: The aim is to critically review studies applying neuroimaging to GBA‐associated parkinsonism. METHODS: Literature search was performed using PubMed and EMBASE databases (last search February 7, 2022). Studies reporting neuroimaging findings in GBA‐PD, GD with and without parkinsonism, and GBA‐NMC were included. RESULTS: Thirty‐five studies were included. In longitudinal studies, GBA‐PD patients show a more aggressive disease than iPD at both structural magnetic resonance imaging and 123‐fluoropropylcarbomethoxyiodophenylnortropane single‐photon emission computed tomography. Fluorodeoxyglucose‐positron emission tomography and brain perfusion studies reported a greater cortical involvement in GBA‐PD compared to iPD. Overall, contrasting evidence is available regarding GBA‐NMC for imaging and clinical findings, although subtle differences have been reported compared with healthy controls with no mutations. CONCLUSIONS: Although results must be interpreted with caution due to limitations of the studies, in line with previous clinical observations, GBA‐PD showed a more aggressive disease progression in neuroimaging longitudinal studies compared to iPD. Cognitive impairment, a “clinical signature” of GBA‐PD, seems to find its neuroimaging correlate in the greater cortical burden displayed by these patients as compared to iPD. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society John Wiley & Sons, Inc. 2022-05-06 2022-07 /pmc/articles/PMC9546404/ /pubmed/35521899 http://dx.doi.org/10.1002/mds.29047 Text en © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Regular Issue Articles
Filippi, Massimo
Balestrino, Roberta
Basaia, Silvia
Agosta, Federica
Neuroimaging in Glucocerebrosidase‐Associated Parkinsonism: A Systematic Review
title Neuroimaging in Glucocerebrosidase‐Associated Parkinsonism: A Systematic Review
title_full Neuroimaging in Glucocerebrosidase‐Associated Parkinsonism: A Systematic Review
title_fullStr Neuroimaging in Glucocerebrosidase‐Associated Parkinsonism: A Systematic Review
title_full_unstemmed Neuroimaging in Glucocerebrosidase‐Associated Parkinsonism: A Systematic Review
title_short Neuroimaging in Glucocerebrosidase‐Associated Parkinsonism: A Systematic Review
title_sort neuroimaging in glucocerebrosidase‐associated parkinsonism: a systematic review
topic Regular Issue Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546404/
https://www.ncbi.nlm.nih.gov/pubmed/35521899
http://dx.doi.org/10.1002/mds.29047
work_keys_str_mv AT filippimassimo neuroimaginginglucocerebrosidaseassociatedparkinsonismasystematicreview
AT balestrinoroberta neuroimaginginglucocerebrosidaseassociatedparkinsonismasystematicreview
AT basaiasilvia neuroimaginginglucocerebrosidaseassociatedparkinsonismasystematicreview
AT agostafederica neuroimaginginglucocerebrosidaseassociatedparkinsonismasystematicreview